Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Rainier Associates.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Rainier Associates
ClinicalTrials.gov Identifier:
NCT00174551
First received: September 9, 2005
Last updated: September 7, 2006
Last verified: September 2005
  Purpose

Investigating the effect of prazosin for nighttime symptoms of civilian Posttraumatic Stress Disorder.


Condition Intervention
Stress Disorders, Post-Traumatic
Drug: prazosin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD

Resource links provided by NLM:


Further study details as provided by Rainier Associates:

Primary Outcome Measures:
  • Sleep time
  • REM sleep time
  • Nightmare frequency
  • CGI

Secondary Outcome Measures:
  • Distressed Awakenings frequency
  • PCL-C

Estimated Enrollment: 20
Study Start Date: November 2003
Estimated Study Completion Date: November 2005
Detailed Description:

Each subject will receive prazosin and placebo trials, the order randomized. Day and nighttime symptoms will be monitored.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • must meet DSM-IV criterion for PTSD

Exclusion Criteria:

  • Must not have untreated sleep apnea
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00174551

Locations
United States, Washington
Fletcher B. Taylor
Tacoma, Washington, United States, 98467
Sponsors and Collaborators
Rainier Associates
Investigators
Principal Investigator: Fletcher B Taylor, M.D. Rainier Associates
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00174551     History of Changes
Other Study ID Numbers: 20031050
Study First Received: September 9, 2005
Last Updated: September 7, 2006
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Mental Disorders
Prazosin
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 22, 2014